NEWSFLOW
Directa Plus (#DCTA) – revenue “acceleration”, but what about the bottom-line?
- 2022-06-17 07:27:23
Producer and supplier of graphene nanoplatelets-based products Directa Plus (DCTA) has announced 2021 results emphasising “revenue and profitability which have exceeded consensus market expectations” and “a number of exciting opportunities in our targeted markets”. So what of a current 121.5p share price?...
Shares in company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) are currently further higher today to 123p on the back of a “US EPA Authorises Grafysorber for Use in US”-titled announcement. What does this latest here mean?...
Having commenced November at a 136p share price, two subsequent announcements have helped shares in Directa Plus (DCTA) up to a current 160p. So what’s this latest news from this ‘graphene nanoplatelets-based products’ company?...
Previously writing on graphene nanoplatelets-based products company Directa Plus (DCTA), in June I concluded with the shares at 121.5p, having expressed cash burn concern, I continued to avoid. Today an “Additional Italian Government Covid Recovery Loan” announcement.
Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) “is pleased to report that this strong revenue growth is continuing in the last two months of the current first half”. What does it mean financially?...
Having exceeded 140p in February, shares in self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) last closed at 112.5p and are currently further lower on the back of 2020 results announcement. So what’s the detail?...
Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has been granted an EU-wide patent covering the use of its G+® graphene in golf ball applications”. It emphasises this “the first step towards addressing a very large global market” and the shares have responded currently 4% higher to 106p, a £65 million market capitalisation. Is this justified?...
Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) has made a trading update including noting 2020 revenue “further improvement” from previously reported expectations, Q1 2021 revenue expected to be up 20% from the same period last year and that “there is a strong pipeline of opportunities”. Why are the shares though still well down from 145p reached earlier this year?...